ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment ConferencePRNewsWire • 08/26/24
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business UpdatePRNewsWire • 08/09/24
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomePRNewsWire • 07/17/24
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdatePRNewsWire • 07/16/24
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferencePRNewsWire • 07/15/24
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionPRNewsWire • 05/15/24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdatePRNewsWire • 05/15/24
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferencePRNewsWire • 05/02/24
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferencePRNewsWire • 04/25/24
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdatePRNewsWire • 04/23/24
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIVNewsfile Corp • 03/21/24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdatePRNewsWire • 03/18/24
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdatePRNewsWire • 03/04/24
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentPRNewsWire • 02/27/24
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI PatientsPRNewsWire • 01/29/24
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024PRNewsWire • 01/23/24
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI PatientsPRNewsWire • 01/17/24
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical CurePRNewsWire • 12/11/23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business UpdatePRNewsWire • 11/14/23